Interestingly, treatment with the non-selective L-type amino acid transporter inhibitor, BCH, was shown to significantly reduce L-Leu uptake in glioma cell lines that express LAT1 and inhibit cell proliferation in a dose-dependent manner [46,63]. Here, SLC7A5 is linked to glioma.